Source:http://linkedlifedata.com/resource/pubmed/id/21772849
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2011-7-20
|
| pubmed:abstractText |
Introduction. A survey was sent to referring oncologists (ROs) to explore the reasons behind their referral patterns and perceptions of Phase I studies before and after being provided with outcome data from advanced colorectal cancer (ACRC) patients who participated in Phase I trials at the Royal Marsden Hospital (RMH). Results. The response rate was 32/50 (64%). The most common reason for referral was exhaustion of standard treatments (31%), and the main reason for referring to the RMH was proximity to patients (28%). The most frequent clinical parameter assessed prior to referral was performance status (93%). ROs spent a median of 15?min (range: 5-45?min) discussing general aspects of Phase I trials. In the second part of the questionnaire, after reviewing clinical outcome data of ACRC patients who participated in Phase I trials, 47% would change their approach, specifically, spend more time to discuss risks and benefits of Phase I trials (9%), consider prognostic factors before referral (13%), and increase the number of referrals (25%). Conclusion. This is the first report focusing on communication between ROs and a specialist Phase I unit. Outcome reporting can improve communication with ROs and importantly has the potential for better patient selection considered for Phase I oncology trials.
|
| pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-10637258,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-10900362,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-12829680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-15523074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-15770219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-1697189,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-17466900,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-17664480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-18349817,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-19169046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-19332724,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-19789331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-7738612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21772849-9924595
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:status |
PubMed-not-MEDLINE
|
| pubmed:issn |
1687-8469
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
2011
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
861401
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Perceptions and referral trends into phase I oncology trials: results of a clinical survey.
|
| pubmed:affiliation |
The Royal Marsden Hospital, Surrey SM2 5PT, UK.
|
| pubmed:publicationType |
Journal Article
|